Sonodynamic-Chemoradiotherapy Integration in Glioblastoma

This Phase II trial tests if sonodynamic therapy (SDT)-a non-invasive treatment using ultrasound to activate a cancer-killing drug-improves outcomes for newly diagnosed glioblastoma patients. Who? 230 adults (\<75 years) with confirmed glioblastoma, adequate organ function, no major health issues. Groups: Test Group: SDT + standard therapy (radiation, chemo, bevacizumab). Control Group: Standard therapy alone. Procedure: SDT uses the drug Hiporfin® followed by focused ultrasound sessions. Patients avoid sunlight for 1 month. Study Duration: Treatment: \~6-8 weeks. Follow-up: 24 months (monthly MRIs). Key Goal: Compare progression-free survival (time until tumor worsens) between groups. Secondary goals: overall survival, safety.